These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 27486306)
21. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429 [TBL] [Abstract][Full Text] [Related]
22. [AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer]. Büchler T; Bobek V; Kološtová K Klin Onkol; 2017; 31(1):9-14. PubMed ID: 29488772 [TBL] [Abstract][Full Text] [Related]
23. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. Njar VC; Brodie AM J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843 [TBL] [Abstract][Full Text] [Related]
25. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590 [TBL] [Abstract][Full Text] [Related]
26. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results]. Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737 [TBL] [Abstract][Full Text] [Related]
27. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281 [TBL] [Abstract][Full Text] [Related]
28. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290 [TBL] [Abstract][Full Text] [Related]
29. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572 [TBL] [Abstract][Full Text] [Related]
30. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Luo J Asian J Androl; 2016; 18(4):580-5. PubMed ID: 27174161 [TBL] [Abstract][Full Text] [Related]
31. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822 [TBL] [Abstract][Full Text] [Related]
32. Role of androgen receptor splice variants, their clinical relevance and treatment options. Wach S; Taubert H; Cronauer M World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302 [TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. Leung JK; Tam T; Wang J; Sadar MD Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481 [TBL] [Abstract][Full Text] [Related]
34. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255 [TBL] [Abstract][Full Text] [Related]
35. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Crona DJ; Milowsky MI; Whang YE Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358 [TBL] [Abstract][Full Text] [Related]
36. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829 [TBL] [Abstract][Full Text] [Related]